** RBC Capital markets upgrades drugmaker Neurocrine Biosciences NBIX.O to "outperform" from "sector perform", trims PT to $137 from $138
** Brokerage expects NBIX's commercial franchise, particularly Ingrezza, to remain solid and durable in the long term, with relatively low exposure to FDA or tariff concerns
** Ingrezza is approved for treating involuntary movements in the face, tongue or other body parts related to Huntington's disease, a genetic brain disorder
** Brokerage sees potential upside in NBIX's pipeline, particularly with experimental drug osavampator, which has shown favorable antidepressive effects and says it could have a potential market size of $1.8 billion if successful
** As of last close, NBIX stock down 33.4% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.